Eisai acquires neuropathy product for China
This article was originally published in Scrip
Eisaihas acquired sales and repackaging rights in China to alpha-Lipon 300 Stada (alpha-lipoic acid), a product for diabetic neuropathy symptoms developed by the German generics firmStada. Eisai's Chinese subsidiary will take over promotional activities from Health Vision Enterprise, a Hong Kong-based Stada development and sales subsidiary, on August 1st, and will seek approval to repackage the product at its plant in Suzhou. The anti-oxidant was launched in China in 2005 for paraesthesia (peripheral numbness) associated with diabetes. Eisai is developing the insulin secretagogue Glufast (mitiglinide, licensed from Kissei) in China, where it already markets Methycobal (mecobalamin) for peripheral nerve disorders.